世界における主要な幹細胞技術企業分析2015-2025

◆英語タイトル:Pharma Leader Series: Top Stem Cell Technology Companies 2015-2025
◆商品コード:VGAIN5040804
◆発行会社(リサーチ会社):visiongain
◆発行日:2015年3月
◆ページ数:200
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle UserGBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Stem cell specialists for healthcare – discover what the future holds for those companies
Who are the top stem cell developers and producers? And what are their sales outlooks? Visiongain’s new report shows you their potentials from 2015. There you discover therapies, results, trends in research and development, opportunities and revenue forecasts.

That way you find data and analysis on cellular technologies transforming human medicine. Our study analyses 23 leading companies in the US, Europe, Israel and Asia-Pacific. There you hear how stem cell producers can progress and gain, discovering their potentials.

Please read on, then, to scan those organisations and find what revenue that fast-growing and potentially large market could generate in future. See what’s possible.

Forecasts and other data to benefit your authority on those biotechnologies and applications
In our new study you find profiles of 23 prominent stem cell companies and analyses of their industry. You explore sales results, R&D advances and revenue forecasting. Explore, from 2015, those firms’ capabilities, portfolios and commercial prospects.

There you also gain 55 tables, 29 charts and six interviews with the industry. Discover views of authorities from ReNeuron, Apceth, Pluristem, Gamida Cell, and others, on that business.

See now how you can benefit your research, analyses and decisions, also saving time and helping your influence and authority on that biotechnology. The following sections explain.

United States (US) – leading organisations and their potentials
First our study gives discussions, analyses and commercial outlooks for 10 US-based stem cell firms:
• Osiris Therapeutics
• NeoStem
• Orthofix
• NuVasive
• AlloSource
• RTI Surgical
• Vericel Corporation
• Bioheart
• Neuralstem
• Ocata Therapeutics.

There you hear what the future holds for those cellular biology companies, including research trends and some revenue predictions to 2025.

Our study then analyses Asian organisations, explaining that region’s potential.

Stem cell specialists based in the Asia-Pacific region – what developments possible?
You also discover commercial outlooks for six top researchers, developers and producers of stem cells in Asia:
• Mesoblast
• Reliance Life Sciences
• Anterogen
• Pharmicell
• MEDIPOST
• Stempeutics.

Our analyses show possibilities for advancing technology and raising business performance, assessing where money lies. Also see revenue forecasting to 2025.

The report then analyses Europe and Israel, showing those countries’ activities and potentials.

Companies based in Europe and Israel – what successes can they achieve?
Our analysis also shows you progress and prospects for seven European and Israeli companies:
• TiGenix
• Cardio3 BioSciences
• Apceth
• ReNeuron
• Gamida Cell
• Cell Cure Neurosciences
• Pluristem Therapeutics.

That work shows where sales growth can occur. Many opportunities remain in that industry, with high, expanding revenues possible from this decade. You also explore clinical testing and plans for launching products.

Our study also assesses that world industry, showing you its potential revenues from 2015 to 2025.

Predictions for the worldwide stem cells market – see that industry’s sales potential
Our report also forecasts revenues to 2025 for the overall world stem cells industry and five submarkets:
• Central nervous system (CNS) uses
• Cardiovascular (CV) applications
• Cancer treatment (oncology)
• Other therapy using those biological agents
• Non-therapeutic cellular products using the technologies.

There you find overall revenues reaching $13.8bn in 2019, with high growth to 2025. Discover what the future holds for those technological advances and their providers.

You also examine forces driving and restraining that industry – social, technological, economic and political forces. And you assess strengths, weaknesses, opportunities and threats.

Technologies and issues shaping that industry and market – explore progress and potential
Our study explains those stem cell technologies and other forces influencing that market. There you explore developments and forces, including these:
• Regulations for that cellular research and technology, and its applications
• Embryonic stem cells – potentials in tissue repair and regenerative medicine
• Autologous and allogeneic agents, including T cell therapy
• Novel treatments for cancer and other applications, e.g. diabetes and bone growth, including progress of clinical trials and product launches.

And also these influences, among others:
• Umbilical cord blood – applications and approvals for that tissue and cell banking
• Regional distribution of the stem cell industry’s 2014 revenues
• Non-therapeutic pharma applications – screening and toxicity studies in drug development.

There you also get interviews with companies, finding information to help you stay ahead on commercial progress, outlooks and future trends. That way, avoid missing out.

【レポートの目次】

1. Report Overview
1.1 Top Stem Cell Technology Companies: Overview
1.2 Global Stem Cell Technology Market Segmentation
1.3 Why You Should Read This Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
1.11 Glossary

2. The Global Stem Cell Technology and Applications Market 2015-2025
2.1 The Stem Cell Technologies and Applications Market in 2014
2.2 Non-therapeutic Applications Constitutes the Largest Segment in 2014, Oncology the Largest Therapeutic Area
2.3 Global Stem Cell Technology and Applications Market: Regional Breakdown, 2014
2.4 Global Stem Cell Technology and Applications Market Forecast 2015-2025
2.5 Fast Growth Owing to Therapeutic Potential, Drug Screening and Emerging Markets
2.6 Global Stem Cell Technology and Applications Market Forecast by Therapeutic Segment 2015-2025
2.7 Therapeutic Applications to Overtake Non-Therapeutic Applications in 2020
2.8 How Will Market Shares for the Different Segments Within the Stem Cells Market Change from 2014-2025?
2.9 Drivers and Restraints for the Stem Cell Technology and Applications Market, 2015-2025

3. Leading US Stem Cell Technology Companies
3.1 Regulation, Patentability and ‘Homologous Use’ in the US
3.1.1 Embryonic Stem Cell Research Remains Controversial in the US
3.2 Osiris Therapeutics
3.2.1 Developed and then Sold the Rights to Osteocel and Prochymal
3.2.2 Grafix Reports Impressive Clinical Trial Results, Now Available in More Sizes
3.2.2.1 Is Grafix Really a ‘Stem Cell Product’?
3.2.3 OvationOS: Stem Cell Product for Regeneration of Bone Tissue
3.2.4 Cartiform – Launched to Address a Potential $500m Market
3.2.4.1 Partnership with Arthrex for the Commercialisation and Development of Cartiform
3.2.5 Osiris Therapeutics Stem Cell Revenue Forecast 2014-2025
3.2.6 Osiris Therapeutics: Optimistic Outlook for that Leading Stem Cell Company
3.3 NeoStem: Generating Revenue through Services whilst Developing Stem Cell Therapies
3.3.1 Growth Through Acquisitions – Including PCT, Amorcyte, Athelos and California Stem Cell Inc.
3.3.2 NBS10 – Lead Candidate in NeoStem’s Ischaemic Repair Programme
3.3.2.1 NBS10 Shows Positive Initial Results From 2014 Phase II Clinical Trial
3.3.3 VSEL Technology: Potential to Treat Ocular Diseases and Chronic Wounds?
3.3.4 NeoStem Revenues 2011-2014
3.3.5 NeoStem Outlook in Summary: NBS10 Could Cater to 160,000 Patients a Year
3.4 Orthofix – Two Orthobiologic Products Already on the Market
3.4.1 Trinity Evolution and Trinity Elite – Over 90,000 Procedures to Date
3.4.1.1 Trinity Elite and Trinity Evolution: Revenue Forecast 2014-2025
3.4.2 Orthofix Outlook in Summary: High Revenues from Trinity Products but Will Have to Demonstrate Efficacy
3.5 NuVasive: Owns the Leading Stem Cell Orthobiologic
3.5.1 Osteocel to Osteocel Plus: Changes and Challenges
3.5.1.1 Osteocel Plus: The Leading Stem Cell Orthobiologic
3.5.1.2 Osteocel Plus: Is it Better than Autograft?
3.5.1.3 Osteocel Plus: Revenue Forecast 2015-2025
3.5.2 NuVasive Outlook in Summary: Osteocel Plus Revenues Will Continue to Grow, Although will Face Increased Competition in Coming Years
3.6 AlloSource: Non-Profit which Markets AlloStem and Processes Osteocel for NuVasive
3.6.1 AlloStem: Stem Cell Bone Growth Substitute
3.7 RTI Surgical: Company adds to their Orthobiologic Portfolio with Map3
3.7.1 Map3: RTI Surgical is Competing with Established Players like NuVasive and Orthofix
3.8 Vericel Corporation (Formerly Aastrom Biosciences)
3.8.1 Ixmyelocel-T
3.8.2 Vericel Focusing on Dilated Cardiomyopathy (DCM) and Away From CLI
3.8.3 Ixmyelocel-T: Orphan Drug Designation and Undergoing Phase 2b Trial for DCM and Phase 1/2 for Craniofacial Reconstruction
3.8.4 Vericel Corporation Revenues 2011-2013
3.8.5 Vericel Corporation: Outlook in Summary
3.9 Bioheart
3.9.1 MyoCell: Autologous ‘Muscle Stem Cell’ Therapy
3.9.1.1 MyoCell: Undergoing Phase 2/3 (‘MARVEL’) Trial
3.9.1.2 MyoCell: MIRROR Phase 3 Trial Progress
3.9.2 MyoCell SDF-1: Improved Version of MyoCell
3.9.2.1 MyoCell SDF-1 Phase 1 Trial (REGEN) Trial
3.9.3 Adipocell for CLI in Phase 1/2, and Being Investigated for RI and Degenerative Disc Disease
3.9.3.1 Adipocell: Also Being Investigated for DDD, COPD and Dry Macular Degeneration
3.9.4 Bioheart Revenues 2010-2013
3.9.5 Bioheart: Outlook in Summary
3.10 Neuralstem
3.10.1 NSI-566 Completes Phase 2 for ALS, Long-Term Follow-Up Data is Promising
3.10.2 NSI-566 for Chronic Spinal Cord Injury: Phase 1, expected to Begin Phase 1/2 for Acute Spinal Cord Injury Q1 2015
3.10.3 NSI-566 for Ischaemic Stroke: Phase 1/2 Trials Underway in China
3.10.4 Neuralstem: Preclinical Investigation for 11 Other Indications
3.10.5 Neuralstem Revenues 2010-2013
3.10.6 Neuralstem Outlook in Summary: Aiming to Treat a Wide Range of Conditions – Potential Revenues are Huge
3.11 Ocata Therapeutics (Formerly Advanced Cell Technology)
3.11.1 Broad Intellectual Property Portfolio and Recent Funding from Lincoln Park Capital
3.11.2 MA09-hRPE in Two Phase 1/2 Trials for Stargardt’s Macular Degeneration
3.11.2.1 Early Signals of Efficacy?
3.11.3 MA09-hRPE: Phase 2 in Dry Age Related Macular Degeneration and Phase 1/2 for Myopic Macular Degeneration
3.11.4 Ocata Therapeutics Revenues, 2011-2013
3.11.5 Ocata Therapeutics: Outlook in Summary
3.12 From Procedures to Products: Cord Blood Stem Cell Approvals
3.12.1 Hemacord by New York Blood Center
3.12.2 HPC, Cord Blood by ClinImmune and University of Colorado Cord Blood Bank
3.12.3 Ducord by Duke University School of Medicine
3.12.4 Allocord by SSM Cardinal Glennon Children’s Medical Center
3.12.5 HPC, Cord Blood BLA 125432 by LifeSouth Community Blood Centers

4. Leading Asia-Pacific Stem Cell Technology Companies
4.1 South Korea: Moving Rapidly to Commercialisation for MSC Therapies – but is it Exercising Enough Caution?
4.2 India: An Emerging Stem Cell Industry
4.3 Japan: Has Been Less Active than other Asian Countries in hESC Research
4.4 China: Liberal Laws for Stem Cell Research
4.5 Mesoblast: Australian Company with Extensive Product Pipeline
4.5.1 Purchase of Prochymal from Osiris and Partnership with Lonza
4.5.2 Prochymal: World’s First Approved Stem Cell Drug Outside of South Korea – Currently has Limited Market Access
4.5.2.1 Prochymal: Culture Expanded and Able to Treat GvHD
4.5.2.2 Mesoblast also Evaluating Prochymal for Treatment of Crohn’s Disease
4.5.2.3 Prochyma: Revenue Forecast, 2015-2025
4.5.3 Mesoblast Evaluating MPCs for Treatment of Diabetes in Phase 2
4.5.4 Mesoblast Evaluating MPCs for Treatment of Rheumatoid Arthritis in Phase 2
4.5.5 CEP-41750 in Phase 3 for Congestive Heart Failure
4.5.6 Phase 2 Trial of MPCs in Acute Myocardial Infarction
4.5.7 Promising Preclinical Findings in Ischaemic Stroke
4.5.8 Phase 2 Trials of MPCs in Intervertebral Disc Repair and Spinal Fusion
4.5.9 Phase 3 Trial in Haematological Malignancies
4.5.10 Phase 2 in Wet AMD, Preclinical In Neurology
4.5.11 Mesoblast Revenues, 2012-2014
4.5.12 Mesoblast Outlook in Summary: Large and Diversified Development Pipeline
4.6 Reliance Life Sciences: Indian Company with Stem Cell Therapies Already on the Market
4.6.1 CardioRel – Already Available in the Indian Market
4.6.1.1 CardioRel: Revenue Forecast, 2015-2025
4.6.2 ReliNethra – The First Stem Cell Therapy in India
4.6.3 ReliNethra C and ReliCord
4.6.4 Reliance Life Sciences: Outlook in Summary – First out of the Gate in the Indian Market, but What about Global Reach?
4.7 Anterogen: South Korean Company with Products Already on the Market
4.7.1 Cupistem: World’s First Approved Stem Cell Product Derived from Adipose Tissue
4.7.2 Queencell: Stromal Vascular Fraction containing Autologous MSCs, and a Phase 1/2 Trial for Treatment of Tennis Elbow
4.7.3 Anterogen: Quick to Market, but How Much Remaining Potential?
4.8 Pharmicell
4.8.1 Hearticellgram-AMI, One of the First Approved Cardiovascular Stem Cell Treatments
4.8.1.1 Hearticellgram-AMI: Potential Difficulty Getting Approval in Markets outside South Korea?
4.8.1.2 Hearticellgram-AMI: Revenue Forecast, 2015-2025
4.8.2 Cerecellgram for Stroke in Phase 3 and Cerecellgram for Spinal Cord Injuries in Phase 2/3: Both Expected to Finish Early 2016
4.8.3 Immunocellgram for Cancers and Lungcellgram for Pulmonary Fibrosis: Both in Preclinical Stages
4.8.4 Cellgram for Erectile Dysfunction – Undergoing Phase 1, and a Treatment for Multiple System Atrophy, Completed Phase 1
4.8.5 Livercellgram for Hepatic Failure: Phase 2 Completed January 2015
4.8.6 Pharmicell Outlook in Summary: Quick to Market and Large Pipeline, but Needs to Make a Push to Expand out of South Korea
4.9 MEDIPOST
4.9.1 Cartistem: ‘World’s First Allogeneic Stem Cell Drug’
4.9.1.1 Cartistem: Revenue Forecast, 2015-2025
4.9.2 Neurostem: Undergoing Phase 1/2a Study
4.9.3 Pneumostem: Undergoing Phase 1 in Intraventricular Haemorrhage and Phase 2 in Bronchial Pulmonary Dysplasia
4.9.4 MEDIPOST Outlook in Summary: One Stem Cell Therapy Already on the Market and South Korea’s Largest Cord Blood Bank
4.10 Stempeutics
4.10.1 Stempeucel: Phase 2 Trials for CLI, Liver Cirrhosis and OA
4.10.2 Stempeucel for Various Other Indications
4.10.3 Alliance with Cipla
4.10.4 Stempeutics Outlook in Summary: Using Stempeucel to Treat a Range of Disorders

5. Leading European Stem Cell Technology Companies
5.1 Regulation in Europe
5.2 UK Leads in European Stem Cell R&D
5.3 TiGenix: Proprietary Technology Platform and Three Stem Cell Products in Development
5.3.1 ChondroCelect Already on the Market
5.3.2 eASC Technology Platform
5.3.3 Cx601: European Phase 3 Data Expected in July 2015
5.3.3.1 Cx601: TiGenix Partners with Lonza, and Will Have Another Phase 3 Trial in the US
5.3.4 Cx611: Phase 2 for Rheumatoid Arthritis, and Phase 1 for Severe Sepsis
5.3.5 Cx621 – Positive Results from Phase 1 Trial
5.3.6 TiGenix Outlook in Summary: Cx601 Reaching End of Development and Represents the Company’s Greatest Strength
5.4 Cardio3 BioSciences: Develops Regenerative Therapies for Cardiovascular Diseases
5.4.1 Cardio3’s Proprietary Cardiopoiesis Technology Platform – Can be Applied to Various Stem Cell Sources
5.4.2 C-Cure: Stem Cell Therapy for the Treatment of Heart Failure
5.4.2.1 Phase 3 Trial Begins Amid Controversy
5.4.3 Cardio3 Outlook in Summary: Targeting a Therapeutic Area with High Unmet Need
5.5 Apceth
5.5.1 Proprietary Technology Platform Delivers Therapeutic Genes Directly to the Target
5.5.2 Agenmestencel-T for the Treatment of GI-tract Adenocarcinoma
5.5.3 Alecmestencel-T for the Treatment of PAOD/CLI
5.5.4 Alecmestencel-L for the Treatment of GvHD
5.5.5 Apceth Outlook in Summary: A Variety of Industry Firsts and Positive Outlook, Although Pipeline is in Early Stages
5.6 ReNeuron: Targeting Areas of Unmet Medical Need
5.6.1 CTX Neural Cell Line: Provides Technical and Competitive Advantages
5.6.1.1 CTX for Stroke: Interim Results from P
ISCES Study Show Positive Results
5.6.1.2 CTX for Stroke: Currently Undergoing Phase 2 Study
5.6.1.3 CTX for Critical Limb Ischaemia: Undergoing Phase 1, will be Completed this Year
5.6.2 hRPCs for the Treatment of Retinitis Pigmentosa: In Late Preclinical Development, Will Begin Clinical Trials Soon
5.6.3 Exosome Technology Platform
5.6.4 Non-therapeutic Products: ReNcell VM and ReNcell CX, Licensed to Merck Millipore
5.6.5 Recent Developments in the Company
5.6.6 ReNeuron Revenue, 2011-2014
5.6.7 ReNeuron Outlook in Summary: Underlying Platform a Major Strength and Source of Competitive Advantage

6. Leading Israeli Stem Cell Technology Companies
6.1 Israel: A Strong Presence in Stem Cell Research
6.2 Gamida Cell
6.2.1 Novartis Buys 15% Equity, Likely to Acquire Fully in 2015, other Investors Include Elbit
6.2.2 NAM Technology Platform
6.2.3 Copper Chelator Based Technology
6.2.4 StemEx Shows Improved Survival at 100 Days, and Other Developments
6.2.5 NiCord – Aiming for a “Paradigm Shift” in Treatment Practice, Receives Orphan Drug Designation
6.2.6 Gamida Cell: Outlook in Summary
6.3 Cell Cure Neurosciences
6.3.1 Using Retinal Pigmented Epithelial Cells to Treat AMD, a Disease Affecting More Than 9 Million People in US
6.3.2 OpRegen and OpRegen Plus: Product Candidates for Dry AMD
6.3.3 Exclusive Licence Agreement with Teva for OpRegen and Possibly OpRegen Plus
6.3.4 Cell Cure Neurosciences: Outlook in Summary
6.4 Pluristem Therapeutics
6.4.1 PLX Cells: Secretes Therapeutic Proteins in Damaged Tissues
6.4.2 PLX-PAD for IC in Phase 2 and for CLI in Phase 1
6.4.3 PLX-PAD for Injured Gluteal Muscle in Phase 1/2 and for PAH in Phase 1
6.4.4 PLX-R18 for ARS, in Preclinical Development
6.4.5 Partnerships with United Therapeutics and CHA Bio & Disotech
6.4.6 Pluristem Therapeutics Revenue, 2012-2014
6.4.7 Pluristem Therapeutics Outlook in Summary: Proprietary Technology and PLX-PAD for Multiple Indications

7. Qualitative Analysis of the Stem Cell Technologies Market, 2015-2025
7.1 SWOT Analysis of the Stem Cell Technologies Market
7.2 Strengths
7.2.1 Recent Approvals of Stem Cell Therapies
7.2.2 Relaxation of Regulatory Barriers
7.2.3 Huge Number of Ongoing Clinical Trials – Should Lead to a Barrage of Approvals over the Coming Years
7.2.4 HSCT is Already an Established Procedure
7.3 Weaknesses
7.3.1 Phase 3 Trials Comprise Only a Small Fraction of Present Studies
7.3.2 Regulatory and Reimbursement Concerns
7.3.3 Uncertain Mechanism of Action in Some Stem Cell Therapies
7.4 Opportunities
7.4.1 Unmet Clinical Needs
7.4.2 Interactions with Related Technologies
7.4.3 Non-Therapeutic Uses: Cord Blood Banking and Cell-Based Assays
7.5 Threats
7.5.1 Financial Risks
7.5.2 Pipeline Failure
7.5.3 Long-term Safety Concerns
7.6 STEP Analysis of the Stem Cell Technologies Market
7.7 Social Factors
7.7.1 Increasing Burden of Disease
7.7.2 Biological Insurance through Stem Cell Banking
7.7.3 Stem Cell Tourism: Opportunities and Threats to the Market
7.8 Technological Factors
7.8.1 Increasing Research Output
7.8.2 IPSC Breakthroughs
7.8.3 Greater Understanding of Stem Cell Differentiation
7.8.4 Biomaterials, Bioprinting and Other Developments
7.8.5 CRISPRS: A Breakthrough in Genome Editing
7.9 Economic Factors
7.9.1 Grey Market for Stem Cell Therapies
7.9.2 Broad Changes in Healthcare Markets
7.9.3 New Business Models need to be Developed
7.10 Political Factors
7.10.1 Controversies and Ethical Objections over Embryonic Stem Cell Research
7.10.2 Strong Support from Some Governments
7.10.3 Pressure to Deregulate the Stem Cell Therapies Market

8. Research Interviews
8.1 Interview with Michael Hunt, Chief Financial Officer, ReNeuron
8.1.1 On the Current Status of ReNeuron’s Pipeline, and Thoughts on Expected Launch Dates and Revenues
8.1.2 ReNeuron’s Development in the Future, Its Biggest Strengths and Challenges and Thoughts on an Acquisition
8.1.3 On the Need for New Frameworks for Therapies and the Progress of the UK Government and Agencies in this Regard
8.1.4 On the Controversies Surrounding Stem Cells, the Global Stem Cell Industry, and Key Trends over the Next Ten Years
8.2 Interview with Steve Choi, Head of Investor Relations, MEDIPOST
8.2.1 On MEDIPOST’s Future and its Biggest Strengths, Opportunities and Challenges
8.2.2 On the Status and Development of its Products and Pipeline
8.2.3 On Competition and the South Korean Market in Relation to the World
8.3 Interview with Stefanos Theoharis, Chief Business Officer, Apceth
8.3.1 Apceth’s Current Aims, and its Development over the Next Ten Years
8.3.2 Apceth’s Greatest Strengths, Opportunities and Challenges
8.3.3 Current Status of the Pipeline, Competition, and Variations Among Markets Around the World
8.3.4 How the Stem Cell Industry Needs to Improve over the next Ten Years
8.4 Interview with Karine Kleinhaus, Divisional Vice President, North America, Pluristem
8.4.1 On Pluristem’s Development over the Next Ten Years
8.4.2 On Pluristem’s Greatest Strengths, Opportunities and Challenges
8.4.3 On the Status of Pluristem’s Pipeline and Results from Clinical Trials
8.4.4 On the Stem Cell Industry in the Next Ten Years
8.5 Interview with Yael Margolin, CEO, Gamida Cell
8.5.1 On the Market Potential of Stem Cell Therapy
8.5.2 On NiCord’s Therapeutic Potential and the Patients Being Targeted
8.5.3 On Immune Rejection, Advantages of Using Stem Cells and how NiCord Compares to Other Products in Clinical Development
8.5.4 Partnership with Teva, the Market Environment and Biggest Threats Facing the Industry
8.6 Interview with Robin Smith, Former CEO of NeoStem
8.6.1 On Whether Stem Cell Therapy can Revolutionise Medicine, as has been Suggested
8.6.2 Advantages of NeoStem’s VSEL Technology, and Target Indications for the Company’s Lead Product Candidate
8.6.3 NeoStem as part of Deloitte’s Technology Fast 500
8.6.4 The Issue of High Prices for Stem Cell Therapies and the Biggest Threats to the Stem Cell Market in the Next Decade
8.6.5 Diseases Generating the Most Interest for Stem Cell Treatment

9. Conclusions
9.1 The US Leads the Field for Stem Cell Research
9.2 Market Remains Under Capitalised, in Need of Financing
9.3 Industry has Many Barriers to Overcome
9.4 Competition Will Increase from 2015 to 2025
9.5 Concluding Remarks

List of Tables
Table 2.1 Breakdown of the Global Stem Cell Technologies and Applications Market by Segment: Revenue ($m), Market Share (%), 2014
Table 2.2 Global Stem Cell Technology and Applications Market: Regional Breakdown: Revenues ($m), Market Share (%), 2014
Table 2.3 Overall World Stem Cell Technology and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 2.4 Overall World Stem Cell Technology and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2020-2025
Table 2.5 Stem Cell Technologies and Applications Market Forecasts by Segment: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 2.6 Stem Cell Technologies and Applications Market Forecasts by Segment: Revenues ($m), AGR (%), CAGR (%), 2020-2025
Table 2.7 Market Shares for the Segments Within the Stem Cell Technology and Applications Market: Revenue ($m), Market Share (%), 2019 and 2025
Table 3.1 Osiris Therapeutics Overview
Table 3.2 Osiris Therapeutics: Stem Cell Revenue Forecast: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2019
Table 3.3 Osiris Therapeutics: Stem Cell Revenue Forecast: Revenue ($m), Annual Growth (%), CAGR (%), 2020-2025
Table 3.4 NeoStem Overview
Table 3.5 NeoStem Revenue Breakdown: Revenue ($m), 2011-2014
Table 3.6 Orthofix Overview
Table 3.7 Orthofix: Trinity Elite and Trinity Evolution Revenue Forecast: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2019
Table 3.8 Orthofix: Trinity Elite and Trinity Evolution Revenue Forecast: Revenue ($m), Annual Growth (%), CAGR (%), 2020-2025
Table 3.9 NuVasive Overview
Table 3.10 NuVasive: Osteocel Plus Forecast: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2019
Table 3.11 NuVasive: Osteocel Plus Sales Forecast: Revenue ($m), Annual Growth (%), CAGR (%), 2020-2025
Table 3.12 AlloSource Overview
Table 3.13 RTI Surgical Overview
Table 3.14 Vericel Corporation Overview
Table 3.15 Vericel Corporation Revenues ($m), 2011-2013
Table 3.16 Bioheart Overview
Table 3.17 Bioheart Revenues ($m), 2010-2013
Table 3.18 Neuralstem Overview
Table 3.19 Neuralstem Revenues ($m), 2010-2013
Table 3.20 Ocata Therapeutics Overview
Table 3.21 Ocata Therapeutics Revenues ($m), 2011-2013
Table 3.22 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2015
Table 4.1 Mesoblast Overview
Table 4.2 Prochymal Forecast: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 4.3 Prochymal Forecast: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2020-2025
Table 4.4 Mesoblast Revenue Breakdown ($m), 2012-2014
Table 4.5 Reliance Life Sciences Overview
Table 4.6 CardioRel Revenue Forecast ($m), 2014-2019
Table 4.7 CardioRel Revenue Forecast ($m), 2020-2025
Table 4.8 Antergoen Overview
Table 4.9 Pharmicell Overview
Table 4.10 Hearticellgram-AMI Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2019
Table 4.11 Hearticellgram-AMI Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2025
Table 4.12 MEDIPOST Overview
Table 4.13 Cartistem Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2019
Table 4.14 Cartistem Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2025
Table 4.15 Stempeutics Overview
Table 5.1 TiGenix Overview 2015
Table 5.2 Cardio3 BioSciences Overview
Table 5.3 Apceth Overview
Table 5.4 ReNeuron Overview
Table 5.5 ReNeuron Revenue Breakdown ($m), 2011-2014
Table 6.1 Gamida Cell Overview
Table 6.2 Cell Cure Neurosciences Overview
Table 6.3 Pluristem Therapeutics Overview
Table 6.4 Pluristem Therapeutics Revenues ($m), 2012-2014
Table 7.1 World Age 65+ Population Forecast: Population (m), AGR (%), CAGR (%), 2014-2019
Table 7.2 World Age 65+ Population Forecast: Population (m), AGR (%), CAGR (%), 2020-2025

List of Figures
Figure 1.1 Global Stem Cell Technology Market Segmentation Overview, 2015
Figure 2.1 Breakdown of the Global Stem Cell Technologies and Applications Market by Segment: Market Share (%), 2014
Figure 2.2 Global Stem Cell Technology and Applications Market: Therapeutic vs Non-therapeutic Applications: Revenue ($m), Market Share (%), 2014
Figure 2.3 Global Stem Cell Technology and Applications Market - Regional Breakdown: Market Share (%), 2014
Figure 2.4 Global Stem Cell Technology and Applications Market Forecast: Revenues ($m), 2014-2025
Figure 2.5 Stem Cell Technologies and Applications Market Forecasts by Segment: Revenues ($m), 2014-2025
Figure 2.6 Market Shares for Segments in the Stem Cell Technology and Applications Market (%), 2019
Figure 2.7 Market Shares for Segments in the Stem Cell Technology and Applications Market (%), 2025
Figure 2.8 Drivers and Restraints for the Stem Cell Technology and Applications Market, 2015-2025
Figure 3.1 Osiris Therapeutics: Stem Cell Forecast: Revenue ($m), 2014-2025
Figure 3.2 NeoStem Revenue Breakdown: Revenue ($m),2011-2014
Figure 3.3 Orthofix: Trinity Elite and Trinity Evolution Forecast: Revenue ($m), 2014-2025
Figure 3.4 NuVasive: Osteocel Forecast: Revenue ($m), 2014-2025
Figure 3.5 Vericel Corporation Revenue ($m), 2011-2013
Figure 3.6 Bioheart Revenue ($m), 2010-2013
Figure 3.7 Neuralstem Revenue ($m), 2010-2013
Figure 3.8 Ocata Therapeutics Revenue ($m), 2011-2013
Figure 4.1 Prochymal Forecast: Revenues ($m), 2014-2025
Figure 4.2 Mesoblast Revenue Breakdown ($m), 2012-2014
Figure 4.3 CardioRel Forecast: Revenue ($m), 2014-2025
Figure 4.4 Hearticellgram-AMI Forecast Revenue ($m), 2014-2025
Figure 4.5 Cartistem Forecast Revenue ($m), 2014-2025
Figure 5.1 ReNeuron Revenue Breakdown, 2011-2014
Figure 6.1 Pluristem Therapeutics: Revenue, 2012-2014
Figure 7.1 Stem Cell Technologies Market: Strengths and Weaknesses, 2015-2025
Figure 7.2 Stem Cell Technologies Market: Opportunities and Threats, 2015-2025
Figure 7.3 Stem Cell Technologies Market: STEP Analysis, 2015-2025
Figure 7.4 World Age 65+ Forecast: Population (m), 2014-2025
Figure 9.1 Nationalities of the Companies Profiled in this Report: Distribution

【掲載企業】

Aastrom Biosciences (now called Vericel Corporation)
Advanced Cell Technology (now called Ocata Therapeutics)
Alkems
Allergan
AlloSource
American Academy of Pediatrics
Amgen
Amorcyte
Anterogen
Apceth
Arthrex
Athelos
Auriga Ventures
BaYi Brain Hospital
Biogenea-Cellgenea
Bioheart
BioTime
Blackstone Medical
California Institute of Regenerative Medicine (CIRM)
California Stem Cell Inc
Cardio3 BioSciences
Carolinas Cord Blood Bank (CCBB)
Casey Eye Institute
Cell Cure Neurosciences
Cellerix
CELLTREE
Cephalon
CHA Bio & Diostech
Cha General Hospital
Chinese Academy of Sciences
Chinese Ministry of Health
Chinese Ministry of Science and Technology
Cipla
CJ CheilJedang
Clal Biotechnologies Industries
Clinicaltrials.gov
ClinImmune Labs
Committee for Advanced Therapies (CAT)
Committee for Medicinal Products for Human Use (CHMP)
Corniche Group
CRISPR Therapeutics
Denali Ventures
Dong-A Pharmaceuticals Co.
Duke University School of Medicine
Elbit Imaging
Elbit Medical Technologies
Eli Lilly
Elsevier
European Commission
European Medicines Agency (EMA)
Forbion Capital Partners
Gamida Cell
Genetrix
Geron
Hadasit Bio-Holdings, Ltd (HBL)
Hadassah University Hospital
Harvard Medical School
Human Fertilisation and Embryology Authority (HFEA)
Human Stem Cells Institute
Indian Department of Biotechnology
International Society for Stem Cell Research (ISSCR)
Israel Healthcare Venture
Israel Stem Cell Society
Japanese Health Ministry
Japanese Institute of Biomedical Research
Japanese Ministry of Economy, Trade and Industry (METI)
JCR pharmaceuticals
Korean Food and Drug Administration (KFDA)
Korean Ministry of Food and Drug Safety (MFDS)
LifeCord
LifeSouth
Lincoln Park Capital Fund
Lonza
Mayo Clinic
MEDIPOST
Medtronic
Merck Millipore
Mesoblast
Musculoskeletal Transplant Foundation (MTF)
National Institute of Health and Care Excellence (NICE)
Nature
NeoStem
Neuralstem
New York Blood Center
New York Heart Association
Novartis
NuVasive
Ocata Therapeutics
Oregon Health and Science University
Orthofix
Osiris Therapeutics
Pharmicell
Phase III Medical Inc.
Pluristem Therapeutics
Progenitor Cell Therapy (PCT)
Reliance Group
Reliance Life Sciences
ReNeuron
Roche
RTI Surgical
Sanofi
Schepens Eye Research Institute
Singapore National Eye Centre
Society for Neuroscience
Society for Stem Cell Research (ISSCR)
SSM Cardinal Glennon Children's Medical Center
St. Louis Cord Blood Bank
StemGen
Stempeutics
Swedish Orphan Biovitrum AB (Sobi)
Teva Pharmaceutical Industries
The Lancet
TiGenix
UK Department of Health and the Medical Research Council
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
United Nations Department of Economic and Social Affairs
United Therapeutics
University of Colorado Anschutz Medical Campus (AMC)
University of Colorado Cord Blood Bank
University of Kyoto
University of Wisconsin Alumni Research Foundation
US Congress
US Department of Defense (DOD)
US Federal Reserve
US Food and Drug Administration (FDA)
US National Academy of Sciences
US National Institute of Health
US Patent and Trademark Office
Vericel Corporation
Viacyte
Yonsei University

【レポートのキーワード】

幹細胞技術、幹細胞開発、企業分析、治療

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界における主要な幹細胞技術企業分析2015-2025(Pharma Leader Series: Top Stem Cell Technology Companies 2015-2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆